Open AccessCD33_PGx6_Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: A Report From the Children’s Oncology Group
Author(s) -
Lata Chauhan,
Miyoung Shin,
Yi Cheng Wang,
Michael R. Loken,
Jessica A. Pollard,
Richard Aplenc,
Betsy Hirsch,
Susana C. Raimondi,
Rhonda E. Ries,
Irwin D. Bernstein,
Alan S. Gamis,
Todd A. Alonzo,
Soheil Meshinchi,
Jatinder K. Lamba
Publication year - 2019
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.18.00387
Subject(s) - gemtuzumab ozogamicin , cd33 , medicine , single nucleotide polymorphism , myeloid leukemia , oncology , snp , genotype , biology , genetics , stem cell , cd34 , gene
The US Food and Drug Administration recently announced reapproval of gemtuzumab ozogamicin (GO) for treatment of CD33-positive acute myeloid leukemia (AML), thus opening up opportunities to develop strategies for effective use of GO. In light of our recent report showing prognostic significance of CD33 splicing single nucleotide polymorphisms (SNPs), the objective of this study was to comprehensively evaluate CD33 SNPs for accurate prediction of patients with AML who are more or less likely to respond to GO.